NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD
1.48
+0.07 (+4.94%)
The current stock price of EVGN is 1.48 USD. In the past month the price decreased by -5.13%. In the past year, price decreased by -84.09%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
EVOGENE LTD
13 Gad Feinstein Street, Park Rehovot
Rehovot 7414002 IL
CEO: Ofer Haviv
Employees: 142
Company Website: https://evogene.com/
Investor Relations: http://investors.evogene.com/
Phone: 97289311900
The current stock price of EVGN is 1.48 USD. The price increased by 4.94% in the last trading session.
The exchange symbol of EVOGENE LTD is EVGN and it is listed on the Nasdaq exchange.
EVGN stock is listed on the Nasdaq exchange.
8 analysts have analysed EVGN and the average price target is 8.29 USD. This implies a price increase of 459.97% is expected in the next year compared to the current price of 1.48. Check the EVOGENE LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EVOGENE LTD (EVGN) has a market capitalization of 7.95M USD. This makes EVGN a Nano Cap stock.
EVOGENE LTD (EVGN) currently has 142 employees.
EVOGENE LTD (EVGN) has a support level at 1.35 and a resistance level at 1.49. Check the full technical report for a detailed analysis of EVGN support and resistance levels.
The Revenue of EVOGENE LTD (EVGN) is expected to grow by 38.71% in the next year. Check the estimates tab for more information on the EVGN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EVGN does not pay a dividend.
EVOGENE LTD (EVGN) will report earnings on 2025-05-21, before the market open.
EVOGENE LTD (EVGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.11).
The outstanding short interest for EVOGENE LTD (EVGN) is 0.3% of its float. Check the ownership tab for more information on the EVGN short interest.
ChartMill assigns a technical rating of 1 / 10 to EVGN. When comparing the yearly performance of all stocks, EVGN is a bad performer in the overall market: 91.48% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -3.11. The EPS increased by 41.32% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -58.62% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to EVGN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -2% and a revenue growth 38.71% for EVGN